NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
Rhea-AI Summary
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.
AI-generated analysis. Not financial advice.
Positive
- Median survival +14.9 months (36.3 vs 21.4 months)
- Hazard ratio 0.35 indicating 65% reduction in risk of death
- Survival benefit reached statistical significance (log-rank p=0.0218; Cox p=0.0037)
- Prior findings included statistically significant slowing of disease progression with favorable safety
Negative
- Small randomized cohort of 68 patients limits broad generalizability
- Placebo-to-active crossover/open-label design may confound long-term between-arm comparisons
- Data from Phase 2b only; pivotal late-stage trials and regulatory review remain required
News Market Reaction – NRSN
On the day this news was published, NRSN declined 14.69%, reflecting a significant negative market reaction. Argus tracked a peak move of +13.7% during that session. Argus tracked a trough of -21.2% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $33.11M at that time. Trading volume was very high at 4.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While NRSN was down 3.85%, peers in momentum scanners were mixed: ITRM and ALLR were up sharply, while RNTX and CVKD were down, indicating stock-specific factors rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | IP / patent grant | Positive | +8.5% | Australian patent grant extending PrimeC composition protection through October 2042. |
| Jan 21 | IP / Alzheimer’s patent | Positive | -5.2% | U.S. patent for PrimeC in Alzheimer’s with protection through 2043 and PoC study update. |
| Jan 08 | SAB appointment | Positive | +12.4% | Alzheimer’s expert joining SAB alongside positive safety data in RoAD study. |
| Dec 22 | Alzheimer’s trial safety | Positive | +3.8% | Phase 2 Alzheimer’s study showing favorable tolerability with no serious adverse events. |
| Dec 04 | Regulatory planning | Positive | -3.5% | Resumed Canadian regulatory activity and planning for pre‑NDS meeting in April 2026. |
Positive news has produced mixed reactions: three prior upbeat updates saw gains, while two similarly positive items coincided with next-day declines.
Over the past few months, NeuroSense has focused on strengthening PrimeC’s clinical and intellectual property position. Patent grants in Australia and the U.S. extended protection into 2042 and 2043, while regulatory work in Canada advanced toward a potential NDS submission by mid‑2026. Alzheimer’s Phase 2 work has emphasized favorable safety, tolerability, and biomarker signals. Against this backdrop, today’s long-term ALS survival data add to the existing Phase 2b PARADIGM dataset, reinforcing PrimeC’s late-stage development narrative built across these prior milestones.
Regulatory & Risk Context
An active Form F-3 shelf filed on 2026-01-29 allows NeuroSense to offer up to $150,000,000 of securities, including support for an at-the-market program of up to $6,525,000. The filing carries forward $85,778,066 of unsold securities from a prior F-3 and notes substantial doubt about the company’s ability to continue as a going concern, underscoring reliance on future financings under this shelf.
Market Pulse Summary
The stock dropped -14.7% in the session following this news. A negative reaction despite statistically significant survival gains—median survival of 36.3 vs 21.4 months and a 65% risk reduction—would fit a pattern where positive news sometimes coincided with declines. Investors have previously sold on good regulatory or IP developments. The existing $150,000,000 shelf filed on 2026-01-29 and disclosed going‑concern risks may have kept attention on potential future financing rather than solely on the strength of the ALS data.
Key Terms
kaplan–meier survival medical
median survival medical
log-rank test medical
cox proportional hazards model medical
hazard ratio medical
open-label medical
double-blind medical
placebo-controlled medical
AI-generated analysis. Not financial advice.
The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in overall survival for patients treated with PrimeC, compared to those initially assigned to placebo.
According to Kaplan–Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved an estimated median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo during the double-blind phase and crossing over to active treatment during the open label extension. This represents over 14-month improvement and approximately a
A log-rank test comparing survival curves demonstrated statistical significance (p = 0.0218).
Further analysis using a Cox proportional hazards model showed that PrimeC treatment was associated with a
"The long-term survival data further validate the magnitude and durability of PrimeC's effect in ALS and reinforce its potential as a disease-modifying therapy," said Alon Ben-Noon, CEO of NeuroSense. "A
The PARADIGM Phase 2b trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of PrimeC in 68 people living with ALS. Participants were administered PrimeC or placebo at a 2:1 ratio, respectively, for the six-month double-blind part. NeuroSense previously reported positive top-line results from the trial, including statistically significant slowing of disease progression and favorable safety and tolerability. The newly reported survival findings represent additional meaningful data generated from the same completed study, further enhancing the overall data package supporting PrimeC.
NeuroSense continues to engage with regulatory authorities regarding the advancement of PrimeC into pivotal late-stage development and believes these findings add important long-term clinical context to previously reported efficacy results.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:SOURCE NeuroSense